Biogen is one of the world’s leading biotechnology companies, developing medicines that change the lives of people living with neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company was founded in Zurich, Switzerland by scientists who were the first to clone and express interferon, the monoclonal antibody that led to the development of our first multiple sclerosis (MS) therapy, AVONEX®. Today, Biogen Idec’s research efforts are built on understanding the underlying biology of complex diseases with a focus on developing therapies for patients with serious illnesses that currently have few, if any, treatment options. Beyond biology, Biogen Idec is using a significant number of major drug discovery and development platforms to identify and bring new treatments to patients. see